The Food and Drug Administration announced it has approved daratumumab and hyaluronidase-fihj, or Darzalex Faspro from Janssen Biotech, in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson call volume above normal and directionally bullish
- Johnson & Johnson Trending as Analysts Stick With Buy
- Top 3 Stocks to Watch Right Now, According to AI Analyst, 1/23/2026
- Johnson & Johnson Stock Trending Higher Among Analysts
- Johnson & Johnson price target raised to $240 from $227 at Guggenheim